Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00444574 is registered in ClinicalTrials.gov with Noven Therapeutics as lead sponsor.

NCT NCT00444574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00444574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Lead sponsor
Noven Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2004
Completion date
June 30, 2005
Enrollment
282 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder